Larimar Therapeutics, Inc. (LRMR) Misses Q4 EPS by 14c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q4 EPS of ($0.45), $0.14 worse than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Momentic Launches the First Agentic Quality Platform as AI Continues to Scale Code Output
• BofA lists top 5 themes driving next $1tn in incremental semi sales